SABR for operable stage I non-small-cell lung cancer: comparison to surgery

Affiliations

Comment

Tairo Kashihara. Lancet Oncol. 2021 Dec.

. 2021 Dec;22(12):e534.

doi: 10.1016/S1470-2045(21)00594-5.

¹ Department of Radiation Oncology in National Cancer Centre Hospital, Tokyo 1040045, Japan. Electronic address: tkashiha@ncc.go.jp.

No abstract available

Conflict of interest statement

I report lecture fees from AstraZeneca, outside the submitted work.

Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, McRae SE, Berry D, Heymach JV, Roth JA; STARS Lung Cancer Trials Group. Chang JY, et al. Lancet Oncol. 2021 Oct;22(10):1448-1457. doi: 10.1016/S1470-2045(21)00401-0. Epub 2021 Sep 13. Lancet Oncol. 2021. PMID: 34529930 Free PMC article. Clinical Trial.
SABR for operable stage I non-small-cell lung cancer: comparison to surgery.
Luo MS. Luo MS. Lancet Oncol. 2021 Dec;22(12):e535. doi: 10.1016/S1470-2045(21)00632-X. Lancet Oncol. 2021. PMID: 34856145 No abstract available.
SABR for operable stage I non-small-cell lung cancer: comparison to surgery.
Zhang J, Liu L, Zhao K, Guo C, Li S. Zhang J, et al. Lancet Oncol. 2021 Dec;22(12):e536. doi: 10.1016/S1470-2045(21)00656-2. Lancet Oncol. 2021. PMID: 34856146 No abstract available.
SABR for operable stage I non-small-cell lung cancer: comparison to surgery - Authors' reply.
Chang JY, Verma V, Feng L, Roth JA. Chang JY, et al. Lancet Oncol. 2021 Dec;22(12):e537-e538. doi: 10.1016/S1470-2045(21)00668-9. Lancet Oncol. 2021. PMID: 34856147 No abstract available.